Cas:478148-61-7 Furo[2,3-c]pyridine-5-carbaldehyde manufacturer & supplier

We serve Chemical Name:Furo[2,3-c]pyridine-5-carbaldehyde CAS:478148-61-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Furo[2,3-c]pyridine-5-carbaldehyde

Chemical Name:Furo[2,3-c]pyridine-5-carbaldehyde
CAS.NO:478148-61-7
Synonyms:Furo[2,3-c]pyridine-5-carboxaldehyde;Furo[2,3-c]pyridine-5-carbaldehyde
Molecular Formula:C8H5NO2
Molecular Weight:147.131
HS Code:2934999090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:261.1±20.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.664
PSA:43.10000
Exact Mass:147.032028
LogP:0.89

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Furo[2,3-c]pyridine-5-carboxaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Furo[2,3-c]pyridine-5-carbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Furo[2,3-c]pyridine-5-carboxaldehyde Use and application,Furo[2,3-c]pyridine-5-carboxaldehyde technical grade,usp/ep/jp grade.


Related News: Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed. Furo[2,3-c]pyridine-5-carbaldehyde manufacturer The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. Furo[2,3-c]pyridine-5-carbaldehyde supplier The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. Furo[2,3-c]pyridine-5-carbaldehyde vendor This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. Furo[2,3-c]pyridine-5-carbaldehyde factory There are also new directives that relate to US citizens.